215 related articles for article (PubMed ID: 32293442)
41. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.
Mouneimné H; Robert J; Jarlier V; Cambau E
Antimicrob Agents Chemother; 1999 Jan; 43(1):62-6. PubMed ID: 9869566
[TBL] [Abstract][Full Text] [Related]
42. [Fluoroquinolone resistance mutations in topoisomerase genes of Salmonella typhimurium isolates].
Guo Y; Pei X; Liu X
Wei Sheng Yan Jiu; 2004 Sep; 33(5):591-4. PubMed ID: 15612489
[TBL] [Abstract][Full Text] [Related]
43. Acquired fluoroquinolone resistance genes in corneal isolates of Pseudomonas aeruginosa.
Khan M; Summers S; Rice SA; Stapleton F; Willcox MDP; Subedi D
Infect Genet Evol; 2020 Nov; 85():104574. PubMed ID: 32992031
[TBL] [Abstract][Full Text] [Related]
44. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
Turner AK; Nair S; Wain J
J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
[TBL] [Abstract][Full Text] [Related]
45. Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin.
Gebru E; Choi MJ; Lee SJ; Damte D; Park SC
J Med Microbiol; 2011 Oct; 60(Pt 10):1512-1522. PubMed ID: 21596912
[TBL] [Abstract][Full Text] [Related]
46. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
Lee JK; Lee YS; Park YK; Kim BS
Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
[TBL] [Abstract][Full Text] [Related]
47. Susceptibility of canine and feline bacterial pathogens to pradofloxacin and comparison with other fluoroquinolones approved for companion animals.
Schink AK; Kadlec K; Hauschild T; Brenner Michael G; Dörner JC; Ludwig C; Werckenthin C; Hehnen HR; Stephan B; Schwarz S
Vet Microbiol; 2013 Feb; 162(1):119-26. PubMed ID: 22939523
[TBL] [Abstract][Full Text] [Related]
48. The role of Gene Mutations (
Arabameri N; Heshmatipour Z; Eftekhar Ardebili S; Jafari Bidhendi Z
Iran J Pathol; 2021; 16(4):426-432. PubMed ID: 34567192
[TBL] [Abstract][Full Text] [Related]
49. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
[TBL] [Abstract][Full Text] [Related]
50. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
Korzheva N; Davies TA; Goldschmidt R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
[TBL] [Abstract][Full Text] [Related]
51. Fluoroquinolone resistance linked to both gyrA and parC mutations in the quinolone resistance-determining region of Shigella dysenteriae type 1.
Talukder KA; Khajanchi BK; Islam MA; Islam Z; Dutta DK; Rahman M; Watanabe H; Nair GB; Sack DA
Curr Microbiol; 2006 Feb; 52(2):108-11. PubMed ID: 16450072
[TBL] [Abstract][Full Text] [Related]
52. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
53. Novel mutations in gyrA and parC among Shigella sonnei strains from Jiangsu Province of China, 2002-2011.
Gu B; Qin TT; Fan WT; Bi RR; Chen Y; Li Y; Ma P
Int J Infect Dis; 2017 Jun; 59():44-49. PubMed ID: 28392317
[TBL] [Abstract][Full Text] [Related]
54. Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa.
Nakano M; Deguchi T; Kawamura T; Yasuda M; Kimura M; Okano Y; Kawada Y
Antimicrob Agents Chemother; 1997 Oct; 41(10):2289-91. PubMed ID: 9333065
[TBL] [Abstract][Full Text] [Related]
55. [Mutations of gyrA gene and parC gene in fluoroquinolone-resistant Escherichia coli isolates from sporadic diarrheal cases].
Ishiguro F; Toho M; Yamazaki M; Matsuyuki S; Moriya K; Tanaka D; Isobe J; Kyota Y; Muraoka M
Kansenshogaku Zasshi; 2006 Sep; 80(5):507-12. PubMed ID: 17073264
[TBL] [Abstract][Full Text] [Related]
56. Characterization of
Farahi RM; Ali AA; Gharavi S
Iran J Microbiol; 2018 Aug; 10(4):242-249. PubMed ID: 30483376
[TBL] [Abstract][Full Text] [Related]
57. [Drug resistance and related genes of chickenborne Salmonella to quinolone and fluoroquinolones].
Hao H; Yang B; Shi J; Xi M; Wang X; Cui Y; Meng J
Wei Sheng Wu Xue Bao; 2011 Oct; 51(10):1413-20. PubMed ID: 22233064
[TBL] [Abstract][Full Text] [Related]
58. Novel mutations in quinolone resistance-determining regions of gyrA, gyrB, parC and parE in Shigella flexneri clinical isolates from eastern Chinese populations between 2001 and 2011.
Qin T; Bi R; Fan W; Kang H; Ma P; Gu B
Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):2037-2045. PubMed ID: 27620866
[TBL] [Abstract][Full Text] [Related]
59. Microbial virulence, molecular epidemiology and pathogenic factors of fluoroquinolone-resistant Haemophilus influenzae infections in Guangzhou, China.
Chen D; Wen S; Feng D; Xu R; Liu J; Peters BM; Su D; Lin Y; Yang L; Xu Z; Shirtliff ME
Ann Clin Microbiol Antimicrob; 2018 Nov; 17(1):41. PubMed ID: 30470228
[TBL] [Abstract][Full Text] [Related]
60. Determination of minimum inhibitory concentrations for silver sulfadiazine and other topical antimicrobial agents against strains of Pseudomonas aeruginosa isolated from canine otitis externa.
von Silva-Tarouca MSE; Wolf G; Mueller RS
Vet Dermatol; 2019 Apr; 30(2):145-e42. PubMed ID: 30663140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
